David Shaw’s Prelude Therapeutics PRLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$95.4K Buy
+24,409
New +$120K ﹤0.01% 4714
2023
Q4
– Sell
-49,184
Closed -$152K – 4547
2023
Q3
$152K Sell
49,184
-6,654
-12% -$25K ﹤0.01% 3802
2023
Q2
$251K Buy
55,838
+8,589
+18% +$51.3K ﹤0.01% 3664
2023
Q1
$269K Sell
47,249
-20,756
-31% -$127K ﹤0.01% 3788
2022
Q4
$411K Sell
68,005
-10,876
-14% -$69.7K ﹤0.01% 3961
2022
Q3
$521K Sell
78,881
-36,986
-32% -$249K ﹤0.01% 4021
2022
Q2
$605K Buy
115,867
+92,256
+391% +$470K ﹤0.01% 3990
2022
Q1
$163K Buy
+23,611
New +$216K ﹤0.01% 4919
2021
Q2
– Sell
-12,546
Closed -$544K – 4959
2021
Q1
$544K Buy
+12,546
New +$832K ﹤0.01% 3465

Other funds holding PRLD

David Shaw's PRLD Position: Q3 2026 in Review

David Shaw opened a new position in Prelude Therapeutics (PRLD) in Q3 2026: 24,409 shares worth $95.4K. The stake represents ﹤0.01% of the portfolio and ranks #4714 among its holdings. This is a return to the name: David Shaw previously reported a position in PRLD as recently as Q3 2023.

David Shaw first reported a position in PRLD in Q1 2021 and has held it in 9 quarters since. The position peaked at $605K in Q2 2022. 92 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.

  • David Shaw held 24,409 shares of Prelude Therapeutics worth $95.4K as of Q3 2026.
  • Prelude Therapeutics was a new David Shaw position in Q3 2026.
  • Prelude Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q3 2026, its #4714 holding.
  • David Shaw first reported a position in Prelude Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • David Shaw's Prelude Therapeutics position peaked at $605K in Q2 2022.
  • 92 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.